Drug Trial Radar · NCT07481799
Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oligometastases
Last checked: Nov 19, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Feb 6, 2026
Primary completion
Feb 28, 2029
Study completion Feb 28, 2030
Sponsor
- Lead sponsor
- Ming-Yuan ChenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The combination of local consolidative therapy for oligometastases with systemic therapy offers the potential for clinical cure and significantly prolongs survival in a subset of patients with advanced metastatic disease. However, a considerable proportion of patients still do not benefit from this approach. Becotatug vedotin (MRG003) is an antibody-drug conjugate that carries the payload monomethyl auristatin E (MMAE), a microtubule inhibitor. MMAE has been shown to effectively enhance radiosensitivity in various preclinical tumor models, including head and neck squamous cell carcinoma, liver cancer, gastric cancer, pancreatic cancer, and lung cancer. Furthermore, multiple clinical studies have demonstrated the promising therapeutic potential of vicetuximab in EGFR-positive solid tumors. Based on this background, we plan to conduct a clinical study evaluating the combination of stereotactic body radiotherapy (SBRT) for oligometastases with investigator-selected systemic therapy and Becotatug vedotin (MRG003) in patients with EGFR-positive oligometastatic tumors.
Conditions
- Oligo-metastatic Cancer
Interventions
Becotatug VedotinDrug
Becotatug vedotin was administered intravenously at a dose of 2.0 mg/kg every 3 weeks (Q3W).
SBRTRadiation
All oligometastatic lesions will be treated with SBRT with curative intent. Radiation doses are determined based on published clinical studies
Systemic Therapy/Standard of CareDrug
Systemic therapy /Standard of Care will be determined at the investigator's discretion, in accordance with clinical guidelines and individual patient characteristics.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: 1 year
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The Fifth Affiliated Hospital,Sun Yat-sen University
Zhuhai, Guangdong, China · Not yet recruiting
The Fifth Affiliated Hospital,Sun Yat-sen University
Zhuhai, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.